Urothelial Cancer | Specialty

The OncLive Urology condition center page is a comprehensive resource for clinical news and expert insights on urologic cancers, including prostate cancer, bladder cancer, testicular cancer, penile cancer, and renal cell carcinoma. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in brain cancer.

Overview of Practice Patterns in Urothelial Carcinoma

March 23rd 2023

A panel of four key opinion leaders share real-world urothelial carcinoma practice patterns at their respective institutions.

Erdafitinib Elicits Responses in High- and Intermediate-Risk NMIBC Harboring FGFR3/2 Alterations

March 22nd 2023

Siamak Daneshmand, MD, shed light on the phase 2 THOR-2 study evaluating different cohorts of patients with recurrent NMIBC, key findings from cohorts 2 and 3, and how ongoing research seeks to move the needle forward with novel drug delivery methods.

Maintenance Avelumab Plus Lurbinectedin Under Investigation in Metastatic Urothelial Carcinoma

March 17th 2023

Investigators are assessing the combination of avelumab and lurbinectedin as maintenance therapy for patients with metastatic urothelial carcinoma who achieve a response or stable disease following first-line, platinum-based chemotherapy in a single-arm phase 2 trial.

China’s NMPA Accepts BLA for Enfortumab Vedotin in Locally Advanced/Metastatic Urothelial Cancer

March 10th 2023

The Center for Drug Evaluation of the China National Medical Products Administration has accepted the biologics license application for enfortumab vedotin for the treatment of patients with locally advanced or metastatic urothelial cancer who received prior treatment with a PD-1/L1 inhibitor and platinum-based chemotherapy.

Extended Follow-up Results From CheckMate 274: Adjuvant Nivolumab in MIUC

March 10th 2023

Expert Matthew D. Galsky, MD, shares his perspective on follow-up results from CheckMate 274, which analyzed adjuvant nivolumab in patients with high-risk muscle-invasive urothelial carcinoma.

Updated CheckMate 274 Data Reaffirm Benefit of Adjuvant Nivolumab in Muscle-Invasive Urothelial Carcinoma

March 7th 2023

Matthew Galsky, MD, discusses the key long-term findings and the clinical implications of the updated data from the phase 3 CheckMate 274 trial of nivolumab for the adjuvant treatment of patients with urothelial carcinoma.

Enfortumab Vedotin Plus Pembrolizumab May Address Unmet Need in Advanced Urothelial Cancer

March 2nd 2023

Jonathan E. Rosenberg, MD, discusses key safety and efficacy data from the EV-103 trial supporting supplemental biologics license applications seeking FDA approval of enfortumab vedotin plus pembrolizumab in patients with advanced urothelial cancer.

Dr. Grivas on the Real-World Study of Avelumab Maintenance in Metastatic Urothelial Carcinoma

February 23rd 2023

Petros Grivas, MD, PhD, discusses key baseline characteristics from the real-world PATRIOT II study of first-line avelumab maintenance therapy in metastatic urothelial cancer.

First-line Avelumab Maintenance Under Real-world Evaluation in Metastatic Urothelial Carcinoma

February 20th 2023

The baseline characteristics, treatment patterns, and responses to first-line platinum-based chemotherapy for patients with locally advanced or metastatic urothelial carcinoma receiving avelumab maintenance therapy were consistent with responses to usual therapy paradigms in the first-line induction setting.

Avelumab Efficacy Holds-Up In A Real-World Analysis of Patients With Locally Advanced, Metastatic Urothelial Carcinoma

February 20th 2023

The efficacy profile for avelumab in patients with locally advanced or metastatic urothelial carcinoma was consistent in a real-world setting with what had been reported in the phase 3 JAVELIN Bladder 100 trial.

Atezolizumab/Chemotherapy Trends Toward Improved OS in Urothelial Carcinoma

February 18th 2023

First-line atezolizumab plus platinum-based chemotherapy and gemcitabine trended toward improved overall survival compared with placebo plus chemotherapy in patients with locally advanced or metastatic urothelial carcinoma.

Nivolumab Displays Sustained Survival Benefits in Urothelial Carcinoma

February 18th 2023

At extended follow-up, nivolumab monotherapy showed improved disease-free survival, non-urothelial tract recurrence-free survival, and disease-specific survival vs placebo in patients with resected, high-risk muscle-invasive urothelial carcinoma.

Atezolizumab Monotherapy Falls Short in Exploratory OS Analysis in Untreated Locally Advanced or Metastatic Urothelial Cancer

February 18th 2023

Atezolizumab monotherapy failed to show an improvement in overall survival compared with placebo plus platinum-based chemotherapy and gemcitabine in patients with untreated locally advanced or metastatic urothelial cancer.

Dr. Galsky on Updated Findings From the CheckMate-274 Trial in Urothelial Cancer

February 17th 2023

Matthew Galsky, MD, discusses the key findings from extended follow-up of the phase 3 CheckMate-274 trial in urothelial cancer.

Dr. Berg on Key Ongoing Trials in Metastatic Urothelial Carcinoma

February 14th 2023

Stephanie A. Berg, DO, discusses key ongoing trials in metastatic urothelial carcinoma.

Dr. Singh on the Continued Investigation of Enfortumab Vedotin/Pembrolizumab in Urothelial Cancer

February 13th 2023

Vikas Kumar Singh, MD, discusses the potential benefit of the combination of enfortumab vedotin plus pembrolizumab for the treatment of patients with locally advanced or metastatic urothelial cancer who are not eligible to receive cisplatin-containing chemotherapy.

Dr. Singh on Treatment Updates in Urothelial Carcinoma

February 10th 2023

Vikas Kumar Singh, MD, discusses findings from the phase 3 GETUG-AFU V05 VESPER (NCT01812369) and JAVELIN Bladder 100 (NCT02603432) trials in patients with bladder cancer.

Dr. Berg the Promise of Key Updates in Urothelial Cancer

February 7th 2023

Stephanie A. Berg, DO, discusses the promise of key updates in urothelial cancer, as well as highlights how these updates continue to affect treatment decisions for patients.

RaDaR Assay Predicts Patient Response to Immunotherapy in Stage III Bladder Cancer

February 6th 2023

The RaDaR assay successfully identified the patients with locoregionally advanced urothelial cancer most likely to benefit from treatment with ipilimumab and nivolumab in findings from the second cohort of the phase 1b/2a NABUCCO trial.

Dr. Grivas on Enfortumab Vedotin Plus Pembrolizumab in Metastatic Urothelial Carcinoma

February 6th 2023

Petros Grivas, MD, PhD, discusses the investigation of enfortumab vedotin and pembrolizumab in metastatic urothelial carcinoma.